NCCN Updates colorectal assessment guidelines

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE NATIONAL COMPREHENSIVE CANCER NETWORK updated its clinical practice guidelines in oncology for Genetic/Familial High-Risk Assessment: Colorectal.

  • For colon cancer, the colonoscopy screening recommendations were changed to “Colonoscopy at age 25-30 y or 2-5 y prior to the earliest colon cancer if it is diagnosed before age 30 y and repeat every 1-2 y” from “Colonoscopy at age 30-35 y (may need to be earlier in some families, depending on ages of cancers observed) every 2-3 y, and then after age 40 y every 1-2 y.”
    For extra colonic, 1st sub-bullet was changed to “For endometrial and ovarian cancer, see surveillance for MLH1, MSH2 and EPCAM carriers (See LS-3)” from “Consider prophylactic hysterectomy and BSO in women who have completed childbearing.”
  • A new clinical testing criteria was added for Lynch Syndrome based on personal and family history: “Consider testing individuals with ≥5% risk of LS on any mutation prediction model (eg, MMRpro, PREMM[1,2,6], MMRpredict).”
  • In Juvenile Polyposis Syndrome, a new heading title was added called, “Genetic Testing.”
    The following bullet was added and revised: “Clinical genetic testing is recommended with approximately 50% of JPS cases occurring due to mutations in the BMPR1A and SMAD4 genes. If known SMAD4 mutation in family, genetic testing should be performed within the first 6 months of life due to hereditary hemorrhagic telangiectasia (HHT) risk.”
    “Hemorrhagic Telangiectasia (HHT)” was added to the table with a recommendation, “In individuals with SMAD4 mutations, screen for vascular lesions associated with HHT.” The initiation age was added: “Within first 6 mo of life.”
  • In Colonic Adenomatous Polyposis of Unknown Etiology:
    Personal history of >10-<100 adenomas: Small adenoma burden manageable by colonoscopy and polypectomy, the sub-bullet for management/surveillance was revised: “Clearing of all polyps is recommended preferable but not always possible.Repeat at short interval if residual polyps are present.”
    Personal history of >10- <100 adenomas: Dense polyposis or large polyps not manageable by polypectomy, the management/surveillance was revised: “Subtotal colectomy or proctocolectomy depending on adenoma density and distribution,” and a new bullet was added: “Consider proctocolectomy if there is dense rectal polyposis not manageable by polypectomy.”
    For each family history phenotype, “consider” was added to each of the management/surveillance recommendations and a corresponding footnote “b” was added: “There are limited data to suggest definitive recommendations for when to initiate screening or the interval of screening.”
  • In Peutz-Jeghers Syndrome, MRI was added as a screening procedure option of the small intestine, and age to initiate screening for pancreatic cancer was changed from “25-30 y” to “30-35 y.”

YOU MAY BE INTERESTED IN

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login